Drugs /

darbepoetin alfa

Back to Drugs List

Overview

NCI Definition [1]:
A recombinant analog of the endogenous cytokine erythropoietin, an erythropoiesis-stimulating protein. Due to the addition of two carbohydrate chains, darbepoetin alfa exhibits a three-fold greater half-life than does erythropoietin. Similar to erythropoietin, darbopoietin alfa binds to and activates epoetin receptors, thereby inducing the differentiation and maturation of erythrocyte progenitors, stimulating endothelial cell proliferation, and stimulating B-cell proliferation and immunoglobulin production. (NCI04)

Clinical Trials

View Clinical Trials for darbepoetin alfa

Darbepoetin alfa has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating darbepoetin alfa, 1 is phase 1/phase 2 (1 open).

Myelodysplastic syndromes is the most common disease being investigated in darbepoetin alfa clinical trials [2].

Drug Details

Synonyms [2]:
nesp, darbepoetin alfa [chemical/ingredient], darbepoetin alfa (product), darbepoetin alfa (substance), darbepoetin alfa,recombinant, nespo, novel erythropoiesis stimulating protein, darbepoetin alfa, darbepoetin alfa, aranest, darbepoetin alfa,recombinant, krn321, aranesp, darbepoietin alfa, darbepoetin, 209810-58-2, 30-l-asparagine-32-l-threonine-87-l-valine-88-l-asparagine-90-l-threonineerythropoietin (human), darbepoetin alfa
NCIT ID [1]:
C1878
SNOMED ID [1]:
C-B905F

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.